These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22779764)

  • 1. [Long-term therapy of idiopathic inflammatory bowel disease].
    Lukáš K; Dastych M; Novotný A; Prokopová L; Zbořil V
    Cas Lek Cesk; 2012; 151(5):231-42. PubMed ID: 22779764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug treatment of chronic inflammatory bowel diseases: current status and prospects].
    Seibold F; Wagner AC; Göke B
    Schweiz Med Wochenschr; 2000 Feb; 130(7):222-32. PubMed ID: 10719713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic inflammatory bowel disease: Crohn's disease and ulcerative colitis].
    Fiasse R; Denis MA; Dewit O
    J Pharm Belg; 2010 Mar; (1):1-9. PubMed ID: 20432590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of remission in Crohn's disease.
    Gonvers JJ; Juillerat P; Mottet C; Felley C; Burnand B; Vader JP; Michetti P; Froehlich F
    Digestion; 2005; 71(1):41-8. PubMed ID: 15711049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic principles for chronic inflammatory bowel disease].
    Binder V; Munkholm P
    Ugeskr Laeger; 2001 Jan; 163(1):16-21. PubMed ID: 11586666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunosuppression in inflammatory bowel disease: When, how and how long?].
    Gross V
    Dtsch Med Wochenschr; 2012 Sep; 137(37):1803-5. PubMed ID: 22956222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
    Moum B
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results.
    Lazzerini M; Martelossi S; Marchetti F; Scabar A; Bradaschia F; Ronfani L; Ventura A
    Aliment Pharmacol Ther; 2007 Feb; 25(4):419-27. PubMed ID: 17269997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab in the treatment of steroid-dependent ulcerative colitis.
    Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional medical management of inflammatory bowel disease.
    Burger D; Travis S
    Gastroenterology; 2011 May; 140(6):1827-1837.e2. PubMed ID: 21530749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of chronic inflammatory bowel diseases].
    Beglinger C
    Ther Umsch; 1997 Nov; 54(11):649-53. PubMed ID: 9454368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice.
    Saibeni S; Virgilio T; D'Incà R; Spina L; Bortoli A; Paccagnella M; Peli M; Sablich R; Meucci G; Colombo E; Benedetti G; Girelli CM; Casella G; Grasso G; de Franchis R; Vecchi M
    Dig Liver Dis; 2008 Oct; 40(10):814-20. PubMed ID: 18479986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of patients with difficult-to-treat inflammatory bowel disease.
    van Hogezand RA
    Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of inflammatory bowel disease in adults.
    Katz JA
    J Dig Dis; 2007 May; 8(2):65-71. PubMed ID: 17532817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of inflammatory bowel disease.
    Mascheretti S; Croucher PJ; Schreiber S
    Best Pract Res Clin Gastroenterol; 2004 Jun; 18(3):597-609. PubMed ID: 15157830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece.
    Christodoulou D; Katsanos K; Baltayannis G; Tzabouras N; Tsianos EV
    Hepatogastroenterology; 2003; 50(52):1021-4. PubMed ID: 12845970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease].
    Bayerdörffer E; Bock H
    Leber Magen Darm; 1988 Apr; 18(2):104-13. PubMed ID: 3374251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.